ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 246. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777-81. 247. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338-45. 248. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92. 249. Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, MacDonagh T, Okonko DO, et al. Drug treatment effects in outcomes in heart failure with preserved ejection fraction: a systematic review andmeta-analysis Heart. 2018;104(5):407-15. 250. AronowWS, AhnC, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics plus angiotensin- converting enzyme inhibitors. Am J Cardiol. 1997;80(2):207-9. 251. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac FunctionHeart FailureWith an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42. 252. Massie BM, Carson PE, McMurray JJ, KomajdaM, McKelvie R, ZileMR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. 253. YipGW,WangM,Wang T, Chan S, Fung JW, Yeung L, et al. TheHong Kong diastolic heart failure study: a randomised controlled trial of diuretics, Irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failurewith a normal ejection fraction. Heart. 2008;94(5):573-80. 254. Lewis EF, Lamas GA, O' Meara E, Granger CB, DunlapME, McKelvie RS, et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9(1):83-91. 255. HaykowskyMJ,BrubakerPH,StewartKP,MorganTM,Eggebeen J,Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failureandpreservedejectionfraction.JAmCollCardiol.2012;60(2):120-8. 256. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail. 2010;3(6):659-67. 257. Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol. 2013; 62(7):584-92. 258. D’Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M. Role of biomarkers in cardiac structurephenotyping in heart failure with preservedejection fraction: critical appraisal andpractical use. Eur J Heart Fail. 2015;17(12):1231-9. 259. Shah SJ, KitzmanDW, Borlaug BA, vanHeerebeek L, ZileMR, Kass DA, et al. Phenotype-specific treatment of heart failure with preserved ejection fraction - A multiorgan roadmap. Circulation. 2016;134(1):73-90. 260. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, et al; MIRACLE Study Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346(24):1845-53. 261. BristowMR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al; ComparisonofMedicalTherapy,Pacing,andDefibrillation inHeartFailure (COMPANION) Investigators. Cardiac-resynchronization therapy with orwithout an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-50. 262. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization onmorbidity andmortality in heart failure. N Engl J Med. 2005;352(15):1539-49. 263. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for theprevention of heart-failure events. N Engl J Med. 2009;361(14):1329-38. 264. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy formild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-5. 265. Goldenberg I, Kutyifa V, Klein HU, CannomDS, BrownMW, Dan A, et al. Survival with cardiac-resynchronizationtherapy in mild heart failure. N Engl J Med. 2014;370(18):1694-701. 266. Bertoldi EG, Polanczyk CA, Cunha V, Ziegelmann PK, Beck-da-Silva L, Rohde LE. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care? J Card Fail. 2011;17(10):860-6. 267. Hsu JC, Solomon SD, Bourgoun M, McNitt S, Goldenberg I, Klein H, et al. MADIT-CRT Executive Committee. Predictors of Super-Response to Cardiac Resynchronization Therapy and Associated Improvement in Clinical Outcome The MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) Study. J Am Coll Cardiol. 2012;59(25):2366-73. 268. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al. Effectiveness of cardiac resynchronizationtherapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;123(10):1061-72. 269. BirnieDH,HaA,HigginsonL,SidhuK,GreenM,PhilipponF,etal.Impactof QRSmorphologyanddurationonoutcomesaftercardiacresynchronization therapy: Results from theResynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2013;6(6):1190-8. 270. Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi A, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failurehospitalisation in patients with non-left bundlebranch block QRS morphology: meta-analysis of randomised controlled trials. Heart. 2015;101(18):1456-62. 271. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-93. 272. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32(19):2420-9. 273. Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: a meta-analysis. Europace. 2012;14(10):1490-7. 274. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connolly SJ, et al; RAFT Investigators. Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2012;5(5):566-70. 275. Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. 2011;8(7):1088-94. 276. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M, et al. Cardiac resynchronization therapy in patients with atrial 524